Share Repurchase Program Authorized by Emergent BioSolutions (NYSE:EBS) Board of Directors

Emergent BioSolutions (NYSE:EBS - Get Free Report) announced that its Board of Directors has initiated a share repurchase program on Monday, March 31st, RTT News reports. The company plans to buyback $50.00 million in shares. This buyback authorization permits the biopharmaceutical company to buy up to 19% of its stock through open market purchases. Stock buyback programs are generally a sign that the company's leadership believes its stock is undervalued.

Emergent BioSolutions Trading Down 6.2 %

NYSE EBS traded down $0.30 on Friday, reaching $4.53. The company had a trading volume of 1,317,374 shares, compared to its average volume of 2,647,074. Emergent BioSolutions has a 52 week low of $1.82 and a 52 week high of $15.10. The stock's 50 day moving average is $7.44 and its 200-day moving average is $8.54. The company has a quick ratio of 1.47, a current ratio of 2.88 and a debt-to-equity ratio of 1.30. The stock has a market cap of $246.15 million, a price-to-earnings ratio of -1.10 and a beta of 1.80.

Emergent BioSolutions (NYSE:EBS - Get Free Report) last announced its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.05 EPS for the quarter, beating analysts' consensus estimates of ($0.35) by $0.40. Emergent BioSolutions had a negative return on equity of 9.91% and a negative net margin of 18.55%. The company had revenue of $194.70 million during the quarter, compared to analysts' expectations of $254.67 million. During the same period in the prior year, the business posted ($0.77) EPS. Equities analysts predict that Emergent BioSolutions will post -0.63 earnings per share for the current year.

Remove Ads

Analyst Upgrades and Downgrades

EBS has been the subject of several recent research reports. HC Wainwright reissued a "buy" rating and set a $15.00 price objective on shares of Emergent BioSolutions in a report on Tuesday. StockNews.com downgraded shares of Emergent BioSolutions from a "buy" rating to a "hold" rating in a research note on Wednesday, March 5th.

Insider Activity

In other Emergent BioSolutions news, Director Neal Franklin Fowler sold 35,000 shares of Emergent BioSolutions stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $5.83, for a total value of $204,050.00. Following the sale, the director now directly owns 101,100 shares in the company, valued at approximately $589,413. The trade was a 25.72 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 1.20% of the stock is owned by company insiders.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.